Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study

Kim Fox, Roberto Ferrari, Michal Tendera, Philippe Gabriel Steg, Ian Ford, BEAUTIFUL Steering Committee, Gordon Murray

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study'. Together they form a unique fingerprint.

Medicine & Life Sciences